MMM — Medicare/Medicaid
Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
1st Quarter - Report · 2026
- Filing UUID
6528b1e6-3f86-441f-b62f-b84921b59524- Type
Q1— 1st Quarter - Report- Period
- first_quarter
- Year
- 2026
- Posted
- 2026-04-20 22:17:23
- Income (reported)
- —
- Expenses (reported)
- $1,460,000
- Expenses method
- A
- Filing document
- Open on lda.senate.gov
Registrant (lobbying firm)
- Contact
- JON CAUSEY
- Phone
- +1 202-450-7459
- Address
- zip:20004, city:WASHINGTON, state:DC, street:601 PENNSYLVANIA AVENUE, NW #720
Client
- State
- DC
- Country
- US
- Government-entity client
- false
- Effective date
- 2007-08-13
Issues lobbied + lobbyists
HCR — Health Issues
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share H.R.6130/S.3267, ASAP Act, to provide coverage for blood based biomarker Alzheimer's disease diagnosis H.R.3747, AADAPT Act, to provide for training for primary care for screening, detection and diagnosis for Alzheimer's disease Issues related to the Food and Drug Administration including PDUFA, druga reviews, approval pathways, and clinical trials H.R.1262, Mikaela Naylon Give Kids a Chance Act, reauthorization of FDA Pediatric-Priority Review Voucher Program Postpartum Depression public policy on screening, detection and education
Lobbyists:
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. H.R.4317, PBM Reform Act of 2025 S.3345, PBM Price Transparency and Accountability Act H.R.6837, to amend the Emloyee Retirement Income Security Act of 1974 to ensure PBMs are considered fiduciaries Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotation period between small-molecule and biologic candidates under the Drig Price Negotiation laws H.R.946, ORPHAN CURES Act
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAX — Taxation/Internal Revenue Code
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TRD — Trade (domestic/foreign)
Trade-related public policy around tariffs and intellectual property, no related bills
Lobbyists:
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)